Pharmacology Exam 1–2: Receptors, Drug Binding, Membranes & Carbohydrates

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/67

encourage image

There's no tags or description

Looks like no tags are added yet.

68 Terms

1
New cards

A ligand has KD = 20 nM. What fraction of enzyme is bound at 200 nM?

f = [L]/([L]+KD) = 200/220 = 91%

2
New cards

Kinase inhibitor Ki = 10 nM; assay [ATP] = 5 x Km. What IC50 is measured?

IC50 = Ki(1+[S]/Km) = 10 x 6 = 60 nM

3
New cards

Antagonist KB = 10 nM; you want a 5-fold agonist EC50 shift. What [antagonist]?

5 = 1 + [B]/10 nM, so [B] = 40 nM

4
New cards

Agonist EC50 goes 50 nM to 500 nM with 100 nM antagonist. Find KB.

Dose ratio 10; KB = [B]/(ratio-1) = 100/9 = about 11 nM

5
New cards

Antagonist KD = 5 uM, agonist KL = 5 uM, [agonist] = 50 uM. Displacement EC50?

EC50 = KD(1+[L]/KL) = 5 x 11 = 55 uM

6
New cards

Target KD = 1 nM, off-target KD = 10 uM. Selectivity and ideal concentration window?

S = 10^4; about 10 nM to 1 uM

7
New cards

Why are monosaccharides metabolized quickly but sorbitol is not?

Open-chain carbonyl allows glycolysis; reduction to a polyol removes it

8
New cards

Why is monosaccharide-lectin binding weak, and what drives it?

Little net enthalpy (water H-bonds replaced by sugar H-bonds); entropy from displaced water drives binding

9
New cards

How do Tweens and Spans differ?

Tween: high HLB, oil-in-water emulsions. Span: low HLB, water-in-oil emulsions

10
New cards

Why does cellulose resist digestion while starch does not?

Cellulose is beta(1,4): straight chains with dense intra/inter-chain H-bonds. Starch is alpha(1,4): accessible helical chains that amylase cleaves

11
New cards

How does heparin prevent clotting?

S-domain pentasaccharide binds antithrombin (conformational change), which sequesters Factor Xa; no thrombin, no fibrin

12
New cards

What is glycation and which proteins are most affected?

Spontaneous reaction of reducing sugars with Lys (Schiff base, Amadori, AGEs/CML); long-lived proteins such as collagen and hemoglobin

13
New cards

Why are DNA-targeting drugs so toxic, and how is that managed?

Little difference between normal and cancer DNA, so fast-dividing normal cells are hit; dose-limited, combination chemotherapy used

14
New cards

Where does a nitrogen mustard attack DNA, and what are the consequences?

Guanine N7 via aziridinium intermediate; cross-links, depurination, strand scission, G-T mispairing mutations

15
New cards

Minor groove binder vs intercalator?

Minor groove binder: crescent-shaped, shape complementarity, AT-rich. Intercalator: flat fused aromatic stacking between base pairs

16
New cards

Why does the cleavable complex matter for topotecan?

Topotecan stabilizes the covalent Topo I-DNA (Tyr723) intermediate so DNA cannot religate

17
New cards

Why not design enzyme inhibitors from the substrate?

Substrates bind weakly (~90% occupancy is enough; binding energy pays for conformational change). The transition state binds about 10^-16 M, so mimic that

18
New cards

Why is IC50 not a constant?

It depends on [S] (Cheng-Prusoff: IC50 = Ki(1+[S]/Km)); always greater than Ki

19
New cards

Why do very lipophilic drugs permeate poorly?

High k1 (entry) but low k2 (exit): they enter and get trapped in the membrane

20
New cards

How can you tell passive from carrier-mediated transport?

Passive: linear, non-saturable, not inhibited. Carrier: saturable, inhibitable, structure- and cell-specific

21
New cards

Dose-response shapes: competitive antagonist, noncompetitive antagonist, partial agonist, PAM?

Competitive: parallel right shift. Noncompetitive: lower plateau. Partial agonist: lower plateau, agonist-like. PAM: left shift and/or higher plateau

22
New cards

What proves a receptor is constitutively active?

An inverse agonist lowers response below baseline

23
New cards

Why is flumazenil not a NAM?

It does not move the GABA curve; it competes at the benzodiazepine site and reverses PAM effects (null allosteric ligand)

24
New cards

Why can partial agonists help in schizophrenia?

Antagonist-like when dopamine is excessive, agonist-like when low; keeps D2 signaling near target occupancy regardless of metabolism

25
New cards

True or false: raising agonist concentration overcomes a noncompetitive antagonist.

False

26
New cards

True or false: EC50 always equals KD.

False; only when no competing ligand is present

27
New cards

True or false: glycosides are stable in neutral water because they are acetals.

True; hydrolysis needs acid

28
New cards

True or false: peripheral membrane proteins need detergent to extract.

False; integral proteins do. Peripheral ones come off with higher ionic strength

29
New cards

True or false: fructose triggers satiety signaling like glucose does.

False

30
New cards

True or false: voltage-gated channels are opened by first messengers.

False; voltage change opens them, drugs only modulate

31
New cards

Exam 1: Competitive vs noncompetitive antagonist - effect on EC50 and Emax?

Competitive: EC50 up, Emax unchanged (parallel right shift). Noncompetitive: Emax down, EC50 unchanged

32
New cards

Exam 1: Agonist EC50 is 20 nM alone, 220 nM with 50 nM antagonist. Find KB.

Dose ratio 11; KB = 50/10 = 5 nM

33
New cards

Exam 1: Displacement assay antagonist EC50 = 60 nM, [agonist] = 10 nM, KL = 5 nM. Antagonist KD?

KD = 60/(1+2) = 20 nM

34
New cards

Exam 1: Define partial agonist and why it can act as an antagonist.

Intrinsic activity e between 0 and 1; plateau below Emax; displaces a full agonist and lowers response when signaling is high

35
New cards

Exam 1: What does an inverse agonist show about a receptor?

Constitutive activity; it lowers response below baseline by stabilizing the inactive form

36
New cards

Exam 1: Class, mechanism and speed: nicotinic ACh receptor, insulin receptor, estrogen receptor.

LGIC (ms, pore opens); RTK (autophosphorylation, slower); ligand-activated transcription factor (hours)

37
New cards

Exam 1: Flumazenil reverses diazepam but does not shift the GABA curve. What kind of ligand?

Null allosteric ligand; competes at the benzodiazepine site

38
New cards

Exam 1: Why do enzymes bind the transition state tighter than the substrate, and why does it matter?

Binding the TS lowers activation energy; substrates need only ~90% occupancy, so TS mimics (statins) can reach nM or lower

39
New cards

Exam 1: Ki = 4 nM, [S] = 3 Km. IC50? What if [S] doubles?

IC50 = 4(1+3) = 16 nM; at [S] = 6 Km, IC50 = 28 nM (inhibitor looks weaker)

40
New cards

Exam 1: Target KD = 2 nM, off-target KD = 20 uM. Selectivity and ideal range?

S = 10^4; roughly 20 nM to 2 uM

41
New cards

Exam 1: Aspirin and COX-2: inhibition type and residue modified.

Covalent irreversible; acetylates Ser530

42
New cards

Exam 1: Why target the early rate-limiting step of cholesterol synthesis?

Late-step inhibition accumulates toxic intermediates; HMG-CoA reductase controls flux

43
New cards

Exam 2: Why is lipid flip-flop slow but lateral diffusion fast?

Flip-flop requires stripping water from the polar head group through the hydrophobic core; lateral motion needs only weak van der Waals changes

44
New cards

Exam 2: Explain the logD window for passive permeability.

Max about 1 to 2.5. Hydrophilic: low k1. Very lipophilic: high k1 but low k2, trapped

45
New cards

Exam 2: Three differences between passive and carrier-mediated transport.

Linear vs saturable; not inhibitable vs inhibitable; low vs high structure and cell-type specificity

46
New cards

Exam 2: How is a peripheral vs an integral membrane protein removed?

Peripheral: raise ionic strength. Integral: detergent

47
New cards

Exam 2: Why are sorbitol and mannitol IV osmotic diuretics but oral laxatives?

Polar, impermeable, slowly metabolized. IV: raise plasma osmolality, expand plasma volume, more urine. Oral: stay in gut and hold water

48
New cards

Exam 2: What drives sugar-protein binding; how do iminosugars like miglitol gain potency?

Entropy from displaced water; protonated ring N mimics the positively charged TS, binding Asp/Glu

49
New cards

Exam 2: Compare cellulose, starch, glycogen.

Cellulose: beta(1,4), straight, not digestible, structural. Starch: alpha(1,4) with alpha-1,6 branches every 12-30, digestible, plant storage. Glycogen: alpha, branches every 8-12, animal storage

50
New cards

Exam 2: How does heparin inhibit clotting?

S-domain pentasaccharide binds antithrombin, conformational change, Factor Xa sequestered, no thrombin, no fibrin

51
New cards

Exam 2: How does a nitrogen mustard cross-link DNA?

N lone pair displaces Cl-, aziridinium forms, guanine N7 attacks; second arm repeats at another guanine = interstrand cross-link

52
New cards

Exam 2: Consequences of guanine N7 alkylation.

Weak glycosidic bond, depurination, abasic site, strand scission; G-T mispairing, mutations, secondary cancers

53
New cards

Exam 2: Cisplatin's main DNA lesion and effect.

dGpG N7-N7 intrastrand cross-link; bends DNA, stalls RNA polymerase, apoptosis

54
New cards

Exam 2: How does topotecan kill cells?

Traps the Topo I-DNA cleavable complex (Tyr723 phosphoester) so DNA cannot religate

55
New cards

Exam 3: Why are glycosides more stable than free monosaccharides?

They are acetals with no free carbonyl at neutral pH; acid is needed to hydrolyze them

56
New cards

Exam 3: Cyclodextrin structure and pharmaceutical use.

Cyclic alpha(1,4) glucans (6, 7, 8 units); hydrophobic cavity forms inclusion complexes that raise solubility, stability, bioavailability; do not cross membranes

57
New cards

Exam 3: Lactulose - why a laxative and why useful in hepatic encephalopathy?

Not absorbed, osmotic; colon bacteria make acids that trap ammonia

58
New cards

Exam 3: Tamiflu and zanamivir - target, design origin, effect.

Viral neuraminidase; sialic acid mimics; block release of new virions

59
New cards

Exam 3: Why are hemoglobin and collagen most affected by glycation?

Slow reaction (reducing sugar + Lys: Schiff base, Amadori, AGEs) hits long-lived proteins

60
New cards

Exam 3: IC50 for Ki = 10 nM, [S] = 2 Km; EC50 shift for KB = 10 nM antagonist at 30 nM?

IC50 = 30 nM; dose ratio 4 (EC50 up 4-fold)

61
New cards

Exam 3: Competitive vs noncompetitive antagonism, with examples.

Same vs different site; surmountable vs not. Competitive: propranolol, naloxone. Noncompetitive: perampanel

62
New cards

Exam 3: Why does aripiprazole work in both mania and negative symptoms?

D2/D3 partial agonist (e about 0.6); antagonist-like when dopamine is high, agonist-like when low

63
New cards

Exam 3: Suzetrigine mechanism and importance.

NAM of Nav1.8 (voltage-sensing domain, stabilizes closed state); peripheral nociceptor; first non-opioid for moderate-severe acute pain (FDA 2025)

64
New cards

Exam 3: Why are DNA drugs dose-limited and how does combination chemotherapy help?

Poor selectivity; combinations bypass resistance, add distinct mechanisms, and can include repair inhibitors

65
New cards

Exam 3: Compare minor groove binders and intercalators.

Minor groove: crescent-shaped, AT-rich, shape fit, block proteins. Intercalators: flat fused aromatics stacking between base pairs; with enzyme contacts they can poison topoisomerases

66
New cards

Exam 3: A polar drug has good oral bioavailability. What does that suggest, and what risk applies?

Carrier-mediated uptake; efflux pumps may also remove it, so efflux inhibition can raise levels

67
New cards

Exam 3: Define potency, efficacy, affinity; example of high affinity but low efficacy.

Potency = EC50 position; efficacy = Emax; affinity = 1/Kd. Antagonists or partial agonists

68
New cards

Exam 3: Why does more agonist weaken an antagonist in a displacement assay?

EC50 = KD(1+[L]/KL); EC50 rises as [L] rises